Trader sentiment on Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7 remains evenly split at 50% implied probability for Yes, reflecting prolonged technology evaluation since the October 2024 peptide research collaboration without a full licensing or technology transfer commitment. Bears cite extensions through late 2025 and Lilly's pivot toward oral obesity formulations, while bulls highlight strategic alignment with Lilly's March 2026 $500 million South Korea clinical hub investment—Peptron's home market—and the firm's GMP manufacturing readiness for long-acting peptide injectables targeting GLP-1 agonists. Q2 2026 earnings in late July or interim deal announcements could tip the balance decisively before resolution.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于最新
最新
2026-10-07
最新
最新
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader sentiment on Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7 remains evenly split at 50% implied probability for Yes, reflecting prolonged technology evaluation since the October 2024 peptide research collaboration without a full licensing or technology transfer commitment. Bears cite extensions through late 2025 and Lilly's pivot toward oral obesity formulations, while bulls highlight strategic alignment with Lilly's March 2026 $500 million South Korea clinical hub investment—Peptron's home market—and the firm's GMP manufacturing readiness for long-acting peptide injectables targeting GLP-1 agonists. Q2 2026 earnings in late July or interim deal announcements could tip the balance decisively before resolution.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$8,217结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Trader sentiment on Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7 remains evenly split at 50% implied probability for Yes, reflecting prolonged technology evaluation since the October 2024 peptide research collaboration without a full licensing or technology transfer commitment. Bears cite extensions through late 2025 and Lilly's pivot toward oral obesity formulations, while bulls highlight strategic alignment with Lilly's March 2026 $500 million South Korea clinical hub investment—Peptron's home market—and the firm's GMP manufacturing readiness for long-acting peptide injectables targeting GLP-1 agonists. Q2 2026 earnings in late July or interim deal announcements could tip the balance decisively before resolution.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$8,217结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Trader sentiment on Eli Lilly licensing Peptron's SmartDepot sustained-release platform by October 7 remains evenly split at 50% implied probability for Yes, reflecting prolonged technology evaluation since the October 2024 peptide research collaboration without a full licensing or technology transfer commitment. Bears cite extensions through late 2025 and Lilly's pivot toward oral obesity formulations, while bulls highlight strategic alignment with Lilly's March 2026 $500 million South Korea clinical hub investment—Peptron's home market—and the firm's GMP manufacturing readiness for long-acting peptide injectables targeting GLP-1 agonists. Q2 2026 earnings in late July or interim deal announcements could tip the balance decisively before resolution.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题